WaveSense Announces Strategic Distribution Relationship with Pisces Scientific Ltd. for UK and Ireland Hematology-Oncology Cytogenetics Market

IRVINE, Calif., Sept. 27, 2016 -- WaveSense, Inc. (www.wavesense.com) the leader in targeted cell isolation and enrichment from liquid biopsies, announced today that it has signed a new strategic marketing relationship with Pisces Scientific Ltd., a leading independent diagnostics
distributor in the United Kingdom (UK) and Ireland. Pisces was founded and continues to be dedicated to the importation and distribution of innovative products and instruments for in vitro diagnostic and research labs focusing on cytogenetics, molecular genetics, and molecular pathology. Pisces Scientific will now market and sell the WaveSense CE-IVD marked cell enrichment platform, a growing pipeline of cell enrichment products. Current CE-IVD products include the EpiSep®, direct to slide enrichment technology, as well as their proprietary paramagnetic bead technology for the selective isolation of cells expressing CD138.

William Curtis, WaveSense CEO, said that “Pisces Scientific has established itself as a trusted distribution partner due to their strong relationships with many of the country’s leading hospital and academic research laboratories.” He added, “We look forward to working with Pisces Scientific and building on the synergy of this partnership. We will work together to meet the growing demands for selective cell enrichment for customers in the UK and Ireland.”

Pisces Scientific Managing Director, Stewart Kennedy, added “As molecular diagnostics become an integral part of the diagnosis and treatment of cancer there is growing concern that the correct cell type is being evaluated. The WaveSense technology directly addresses this concern, and with this partnership, we will now be able to deliver the optimal solution to cytogenetic laboratories within the UK and Ireland.”

WaveSense, Inc. Receives CE-IVD Marking Approval for Its Cell Enrichment Technology Platform

IRVINE, Calif., Sept. 21, 2016 -- WaveSense, Inc. (www.wavesense.com) the leader in targeted cell isolation and enrichment from liquid biopsies, announced today that it has received CE-IVD marking approval for their suite of cell isolation and enrichment technologies. The approval includes the EpiSep® direct to slide enrichment technology as well as their proprietary paramagnetic bead technology for the selective isolation of cells expressing CD138. CE marking allows for marketing and sales of the products in the European Union and other countries. The WaveSense system, a growing pipeline of cell enrichment products, can be used for selective recovery/enrichment of cells expressing the CD138 cell surface antigen in biological fluids and tissue culture.

As molecular diagnostics become an integral part of the diagnosis and treatment of cancer there is growing concern that the correct cell type is being evaluated. This concern is most acute when a negative result is reported. The WaveSense cell enrichment platform is designed to address this issue and is in routine clinical use for multiple liquid biopsy applications, including one for the isolation and capture of positive CD138 cells. This is critical for identifying genomic and proteomic abnormalities in plasma cell neoplasms. A cell enrichment study led by Gary Lu, M.D., Department of Hematopathology, the University of Texas MD Anderson Cancer Center, showed that the median plasma cell percentage in non-enriched bone marrow specimens increased from 8% to 73% in enriched bone marrow specimens, implying a 9-fold increase in diagnostic sensitivity. (Arch Pathol Lab Med—Vol 137, May 2013).

“CE marking approval for the WaveSense product line, a FDA Class I technology, represents a significant milestone and accomplishment by all of the employees of WaveSense,” said CEO William Curtis, “The completion of the registration signifies that we are complying with the high standards of the EU governing authorities in the areas of quality, safety and performance.”

“The CD138 isolation and enrichment product for bone marrow is the company’s immediate commercialization focus in the EU,” added Curtis, who noted that the product is already in use by a growing number of prominent reference laboratories and cancer centers in the US and WaveSense can now replicate this acceptance in many European countries."

New website

Pisces Scientific is proud to announce the launch of our newly redesigned website.

We hope you like the new layout with a modern design and the simple navigation system, making it easier to find the information you are looking for.

The site is now compatible with modern tablets and smart phones to allow you to browse while on the move.

We will be updating our News section and Featured Products regularly where you can find new information about our company and new or topical products.

If you have any questions about our new site or any other matter, then please get in touch via our Contact section.